The Octopus Value Investing

The Octopus Value Investing

Public companies research, value investig philosophy and much more.

Earnings ReviewEarnings Review
+1+1
Novo Nordisk - Q1 2025 Earnings Review

Novo Nordisk - Q1 2025 Earnings Review

When Expectations Are So Low...

The Octopus Value Investing
The Octopus Value Investing
Novo NordiskNovo Nordisk
Novo Nordisk Valuation Update

Novo Nordisk Valuation Update

The Margin of Safety Might Have Never Been Larger

The Octopus Value Investing
The Octopus Value Investing
Theon InternationalTheon International
Theon International - Qualitative Analysis

Theon International - Qualitative Analysis

A High Quality Company in the European Defense Sector

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
+1+1
Pandora A/S - 2024 Earnings Review

Pandora A/S - 2024 Earnings Review

Another Year Surpassing the Expectations Set

The Octopus Value Investing
The Octopus Value Investing
Sectors in briefSectors in brief
#5 Sectors in Brief - Pharmaceutical Packaging Assembly

#5 Sectors in Brief - Pharmaceutical Packaging Assembly

Searching for Investing Opportunities in Another Sector of the Pharmaceutical Industry

The Octopus Value Investing
The Octopus Value Investing
Earnings ReviewEarnings Review
+1+1
Novo Nordisk A/S - 2024 Earnings Review

Novo Nordisk A/S - 2024 Earnings Review

When Expectations Are So Low Tha

The Octopus Value Investing
The Octopus Value Investing
Lonza Group AGLonza Group AG
+1+1
Lonza Group AG - 2024 Earnings Review

Lonza Group AG - 2024 Earnings Review

Lonza Group AG: Resilient Performance Amid Strategic Investments and Cost Discipline

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
+1+1
Schott Pharma AG - 23/24 Earnings Review

Schott Pharma AG - 23/24 Earnings Review

Short-Term Fears Taking over a Earnings Report Within Expectations

The Octopus Value Investing
The Octopus Value Investing
The Octopus PortfolioThe Octopus Portfolio
#3 The Journey of Compounding - 2024 Letter to Readers

#3 The Journey of Compounding - 2024 Letter to Readers

2024 Annual Review to all The Octopus Value Investing readers

The Octopus Value Investing
The Octopus Value Investing
News & Trending TopicsNews & Trending Topics
+1+1
CagriSema Phase III Results Review

CagriSema Phase III Results Review

Novo Nordisk Stock Plunge: Overreaction or Justified?

The Octopus Value Investing
The Octopus Value Investing